RCEL

Over the past six months, AVITA Medical's stock price decreased by 5.86% to $4.18 as of May 7, 2026, with a significant decline of 51.79% from May 5, 2025, to May 1, 2026. Shareholder dilution, marked by an 80% increase in shares outstanding, is a major risk. Despite the falling trend, the stock price rose 49% in the 90 days leading up to May 7, 2026. On April 9, 2026, AVITA Medical secured a 10-year BARDA agreement worth up to $25.5 million, which initially inspired a stock rally. Cary Vance was appointed CEO, and Jan Stern Reed was elevated to Chair of the Board on May 1, 2026. The company filed a $200 million S-3 shelf registration to sell stock and warrants on March 31, 2026. The CFO purchased shares on March 11 and February 23, 2026. The company reported its Q3 2025 earnings on November 6, 2025, with an EPS of -$0.46 and revenue of $17.06 million, missing analyst estimates. Analysts generally have a "Buy" consensus rating with an average price target of $7.88, while an AI model assigned a "Sell" rating.